Literature DB >> 25268086

Wortmannin enhances cisplatin-induced apoptosis in human ovarian cancer cells in vitro.

J-X Zhao1, H Liu, J Lv, X-J Yang.   

Abstract

OBJECTIVE: The PI3K/Akt signaling pathway is constitutively activated in some ovarian cancers; when activated, it promotes invasion and inhibits chemotherapy-mediated apoptosis in cancer cells. The fungal metabolite wortmannin is the currently known inhibitors that show fairly high specificity for PI3K.We examined whether PI3K/Akt activity correlates with invasion and apoptotic resistance to chemotherapy in cultured human ovarian cancer cells, and whether inhibition of PI3K/Akt by wortmannin inhibits invasion and enhances cisplatin-induced apoptosis in cultured human ovarian cancer cells.
MATERIALS AND METHODS: The cisplatin-sensitive A2780 ovarian adenocarcinoma cell line and its daughter line, A2780cis was evaluated for basal Akt activity. Chemotherapy-induced cell death was evaluated following down-regulation of Akt activity by wortmannin treatment or upregulation of Akt activity by myr-Akt treatment. Invasion and migration were assessed using Boyden chamber assays
RESULTS: Inhibiting or activation of PI3K/Akt signaling pathway by wortmannin had little effect on the basal level of apoptosis in ovarian cancer cells, but increased the apoptotic effect of chemotherapy in A2780cis cells, decreased the apoptotic effect of chemotherapy in cisplatin-sensitive A2780 cells. Cisplatin resistant cells display increased potential for migration and invasion.
CONCLUSIONS: The antiapoptotic effect of AKT activation in ovarian cancer cells confer invasive ability and resistance to apoptosis. Wortmannin is as adjuncts to conventional chemotherapy in the treatment of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25268086

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  11 in total

1.  MiR-944 functions as a novel oncogene and regulates the chemoresistance in breast cancer.

Authors:  Haifei He; Wei Tian; Hailong Chen; Kai Jiang
Journal:  Tumour Biol       Date:  2015-08-23

2.  Luteinizing hormone inhibits cisplatin-induced apoptosis in human epithelial ovarian cancer cells.

Authors:  Lingfang Xia; Hao Wen; Xiaotian Han; Jia Tang; Yan Huang
Journal:  Oncol Lett       Date:  2016-01-18       Impact factor: 2.967

3.  MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer.

Authors:  Ruiguang Zhang; Yan Li; Xiaochuan Dong; Li Peng; Xiu Nie
Journal:  Med Oncol       Date:  2014-11-22       Impact factor: 3.064

4.  Do Wortmannin and Thalidomide induce apoptosis by autophagy inhibition in 4T1 breast cancer cells in vitro and in vivo?

Authors:  Elgin Turkoz Uluer; Pinar Kilicaslan Sonmez; Damla Akogullari; Melike Onal; Gamze Tanriover; Sevinc Inan
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

Review 5.  Autophagy Function and Dysfunction: Potential Drugs as Anti-Cancer Therapy.

Authors:  Francesca Cuomo; Lucia Altucci; Gilda Cobellis
Journal:  Cancers (Basel)       Date:  2019-09-29       Impact factor: 6.639

6.  Inhibition of TRIM32 Induced by miR-519d Increases the Sensitivity of Colorectal Cancer Cells to Cisplatin.

Authors:  Xueliang Su; Bangjie Wang; Yehong Wang; Baochun Wang
Journal:  Onco Targets Ther       Date:  2020-01-10       Impact factor: 4.147

Review 7.  Autophagy: a multifaceted player in the fate of sperm.

Authors:  Mei Wang; Ling Zeng; Ping Su; Ling Ma; Ming Zhang; Yuan Zhen Zhang
Journal:  Hum Reprod Update       Date:  2022-02-28       Impact factor: 15.610

8.  Osthole resensitizes CD133+ hepatocellular carcinoma cells to cisplatin treatment via PTEN/AKT pathway.

Authors:  Junfeng Ye; Di Sun; Ying Yu; Jinhai Yu
Journal:  Aging (Albany NY)       Date:  2020-07-16       Impact factor: 5.682

Review 9.  Promising Antineoplastic Actions of Melatonin.

Authors:  Gaia Favero; Enrico Moretti; Francesca Bonomini; Russel J Reiter; Luigi Fabrizio Rodella; Rita Rezzani
Journal:  Front Pharmacol       Date:  2018-10-16       Impact factor: 5.810

10.  miR-34c Targets MET to Improve the Anti-Tumor Effect of Cisplatin on Ovarian Cancer.

Authors:  Shiying Yang; Zhen Li; Rui Luo
Journal:  Onco Targets Ther       Date:  2020-04-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.